I am 24, male with hemophilia A. Can non-factor therapy help?

Question

Hello doctor,

I am a 24-year-old man with hemophilia A, diagnosed in childhood, and my baseline factor VIII activity is less than one percent. I am on prophylactic recombinant factor VIII infusions twice weekly, but I still experience frequent joint bleeds, particularly in my knees and elbows.

My recent hemoglobin is 9.8 g/dL, and ferritin is 12 ng/mL, indicating iron deficiency anemia due to recurrent bleeding. I also have hepatitis C infection, likely from past transfusions, and my latest viral load is 2.3 × 10⁵ IU/mL, with mildly elevated liver enzymes (ALT 72 U/L, AST 65 U/L).

Because of repeated joint bleeds, I have developed chronic arthropathy, and my recent MRI showed cartilage damage in the right knee. My BMI is 19.4 kg/m², and I often feel fatigued and weak. I am currently taking iron supplements, but I still feel tired most of the time.

I would like to know whether switching to extended half-life factor VIII or newer non-factor therapies, such as Emicizumab, could help reduce bleeds and improve my quality of life, especially given my liver condition. Are these treatments safe in someone with hepatitis C and anemia, and are there additional precautions I should take to protect my joints and overall health?

Please advise.

Answer 1

Hello,

Welcome to icliniq.com.

I understand your concern.

You are already on prophylactic recombinant factor VIII but are still experiencing frequent bleeds, especially in target joints (knees and elbows).

Options for better bleed control:

Extended half-life (EHL) factor VIII products: These require fewer infusions per week (once or twice) and provide longer coverage, potentially reducing breakthrough bleeds.
Non-factor therapy (Emicizumab): This is a bispecific monoclonal antibody that mimics factor VIII activity. Clinical trials have shown that it significantly reduces annual bleed rates, even in severe patients, and is particularly beneficial in those with inhibitors or frequent joint bleeds. It is given subcutaneously, which improves convenience and compliance.

Both options are considered safe in patients with hepatitis C and anemia.

Your hemoglobin (9.8 g/dL) and ferritin (12 ng/mL) confirm iron deficiency anemia, most likely due to recurrent bleeding. Oral iron supplementation is appropriate, but it may take time and sometimes is not well absorbed. If your fatigue is severe or your hemoglobin does not improve, intravenous iron infusions may be considered for faster correction. Regularly monitor CBC (complete blood count), ferritin, and transferrin saturation.

Your detectable viral load and elevated ALT (alanine aminotransferase) or AST (aspartate aminotransferase) warrant direct-acting antiviral (DAA) therapy, under the guidance of a physician. Pre-treatment work-up should include: HCV (hepatitis C virus) genotype (if not using a pangenotypic regimen), fibrosis assessment, HBV (hepatitis B virus) screen, HIV (human immunodeficiency virus) test, and ultrasound if advanced fibrosis is suspected. Strictly avoid alcohol. Avoid unnecessary hepatotoxins; keep Paracetamol less than 2 to 3 g/day (adjusted for liver status).

For joint care, structured range-of-motion exercises, quadriceps and hamstring strengthening, and proprioception training, low-impact cardio such as cycling or swimming and use bracing or orthoses during activities that provoke swelling.

Successfully clearing HCV often improves fatigue and overall well-being.

I hope this has helped you.

Please feel free to reach out to me again if you have further queries.

Thank you.